0
ARTICLE |

Costs and Benefits of Preemployment Drug Screening FREE

Craig Zwerling, MD, PhD, MPH; James Ryan, MD, MPH; E. John Orav, PhD
[+] Author Affiliations

The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the US Postal Service or those who so generously helped them.

Reprint requests to the Institute of Agricultural Medicine and Occupational Health, Department of Preventive Medicine and Environmental Health, The University of Iowa, 138 AMRF-Oakdale Campus, Iowa City, IA 52242 (Dr Zwerling).


JAMA. 1992;267(1):91-93. doi:10.1001/jama.1992.03480010099032
Text Size: A A A
Published online

Objective.  —This study provides a cost-benefit analysis of preemployment drug screening and evaluates the sensitivity of this analysis to variation in its underlying assumptions.

Design.  —Cost-benefit analysis, based on a cohort analytic study previously reported.

Setting.  —Employees of the US Postal Service in Boston, Mass.

Participants.  —Estimates of costs and benefit are based on a cohort of 2533 postal workers in Boston and on average costs for the Postal Service in Boston and nationwide.

Results.  —Drug screening would have saved the Postal Service $162 per applicant hired. However, these results were sensitive to the assumptions in the model. If the prevalence of drug use in the population screened were 1% rather than 12%, the program would lose money. Similarly, if the cost per urine sample screened were $95 rather than the $49 assumed, then the program would lose money, even if the prevalence of drug positives was as high as 9%.

Conclusions.  —Because of the sensitivity of this analysis to changes in its underlying assumptions, any company considering preemployment drug screening should carefully weigh the costs and benefits in its own industry.(JAMA. 1992;267:91-93)

REFERENCES

Survey of Employer Anti-Drug Programs . Washington, DC: Bureau of Labor Statistics; 1989;. US Department of Labor report 760.
Hayghe HV.  Anti-drug programs in the workplace: are they here to stay? Monthly Labor Rev . (April) 1991;:26-29.
Harwood HJ, Napolitano DM, Kristiansen PL, Collins JJ. Economic Costs to Society of Alcohol and Drug Abuse and Mental Illness: 1980 . Research Triangle Park, NC: Research Triangle Institute; 1984;. RT1/2734/00-01FR.
Lundberg G.  Mandatory unindicated urine drug screening: still chemical McCarthyism. JAMA . 1986;;256:3005.
Zwerling CS, Ryan JR, Orav EJ.  The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. JAMA . 1990;;264:2639-2643.
Normand J, Salyards SD, Mahoney JJ.  An evaluation of preemployment drug testing. J Appl Psychol . 1990;;75:629-639.
Warner KE, Luce BR. Cost-benefit and Cost-effectiveness Analysis and Health Care: Principles, Practice, and Potential . Ann Arbor, Mich: Health Administration Press; 1982;:93-98.
 Court backs tests of some workers to deter drug use. New York Times . (March 22) , 1989;:A1.
Employee Drug Testing: Agency Costs May Vary From Earlier Estimates . Washington, DC: United States General Accounting Office; 1989;. US General Accounting Office publication GAO/GGD-89-75.
Freudenheim M.  Booming business: drug use tests. New York Times . (January 3) , 1990;:D1-D2.
Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs . New York, NY: Oxford University Press;1987;:72-73.
Sexton TR, Zilz U.  On the wisdom of mandatory drug testing. J Policy Anal Manage . 1988;;7:542-547.
Wells VE, Halperin W, Thun M.  The estimated predictive value positive of screening for illicit drugs in the workplace. Am J Public Health . 1988;;78:817-819.
Spiehler VR, O'Donnell CM, Gokhale DV.  Confirmation and certainty in toxicology screening. Clin Chem . 1988;;34:1535-1539.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Survey of Employer Anti-Drug Programs . Washington, DC: Bureau of Labor Statistics; 1989;. US Department of Labor report 760.
Hayghe HV.  Anti-drug programs in the workplace: are they here to stay? Monthly Labor Rev . (April) 1991;:26-29.
Harwood HJ, Napolitano DM, Kristiansen PL, Collins JJ. Economic Costs to Society of Alcohol and Drug Abuse and Mental Illness: 1980 . Research Triangle Park, NC: Research Triangle Institute; 1984;. RT1/2734/00-01FR.
Lundberg G.  Mandatory unindicated urine drug screening: still chemical McCarthyism. JAMA . 1986;;256:3005.
Zwerling CS, Ryan JR, Orav EJ.  The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. JAMA . 1990;;264:2639-2643.
Normand J, Salyards SD, Mahoney JJ.  An evaluation of preemployment drug testing. J Appl Psychol . 1990;;75:629-639.
Warner KE, Luce BR. Cost-benefit and Cost-effectiveness Analysis and Health Care: Principles, Practice, and Potential . Ann Arbor, Mich: Health Administration Press; 1982;:93-98.
 Court backs tests of some workers to deter drug use. New York Times . (March 22) , 1989;:A1.
Employee Drug Testing: Agency Costs May Vary From Earlier Estimates . Washington, DC: United States General Accounting Office; 1989;. US General Accounting Office publication GAO/GGD-89-75.
Freudenheim M.  Booming business: drug use tests. New York Times . (January 3) , 1990;:D1-D2.
Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs . New York, NY: Oxford University Press;1987;:72-73.
Sexton TR, Zilz U.  On the wisdom of mandatory drug testing. J Policy Anal Manage . 1988;;7:542-547.
Wells VE, Halperin W, Thun M.  The estimated predictive value positive of screening for illicit drugs in the workplace. Am J Public Health . 1988;;78:817-819.
Spiehler VR, O'Donnell CM, Gokhale DV.  Confirmation and certainty in toxicology screening. Clin Chem . 1988;;34:1535-1539.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.